The purpose of this Funding Opportunity Announcement (FOA) is to elucidate the etiology and pathogenesis of the neurocognitive complications associated with type 2 diabetes (T2D) with the ultimate goal of informing future strategies to mitigate the risk of these complications. Applications should propose expansions of ongoing human studies of well characterized T2D cohorts or cohorts comparing T2D with non-diabetic populations. Such expansions might include the addition of comprehensive neurocognitive measures (e.g., cognitive testing, neuroimaging, and biomarkers), clinical measures (e.g., insulin resistance, HbA1c), and/or collection of data on other risk factors (e.g., diet, obesity, micro- and macro-vascular disease, inflammation). It must be clearly explained how the collection of additional data will contribute to elucidation of the basis of neurocognitive sequelae of T2D.
Founded in 1972, the Tourette Association of America (formerly known as the Tourette Syndrome Association) has emerged as the premier national nonprofit organization working to make life better for all people affected by Tourette and tic disorders. The association advances its work by raising public awareness and fostering social acceptance; working to advance scientific understanding, treatment options, and care; educating professionals to better serve the needs of children, adults, and families challenged by Tourette and tic disorders; advocating for public policies and services that promote positive school, work, and social environments; providing help, hope, and a supportive community across the nation; and empowering its community to deal with the complexities of this spectrum of disorders.
To that end, grants of up to $150,000 over two years will be awarded for basic and clinical studies on all aspects of Tourette syndrome.
To be eligible, investigators are required to have an advanced degree such as a Ph.D., M.D. or equivalent or be allied professionals with advanced degrees such as R.N.s, Drs. of O.T., social workers, and related fields. Investigators from nonprofit and for-profit organizations can apply.
Applicants for the funds may be students or faculty. The project, program, or entrepreneurial idea must be created by, led by or benefit women.
Grants are awarded in values of $2500 to $20,000. While we prefer the base grant to be $5,000, we are considering a limited number of $2500 which will be required to show high impact. These applicants will be considered on a case-by-case basis.
The grants must be submitted online via the link below and must include a 2-minute video. Applicants will be narrowed to a pool of 10-15 finalists by our M.I.A.M.I. WOMEN Grants Committee. This committee will review applications; contact applicants if additional information is required, and present the finalists to the M.I.A.M.I. WOMEN Steering Committee and Development Staff.
Grant deadline for this year is Feb. 9, 2018.
These finalists will perform in a fast-pitch style Hawk Tank event on April 11, 2018. Finalists will be offered fast-pitch training courtesy of the Farmers School of Business - school of Entrepreneurship, and will receive coaching and support. They will then pitch their idea in 5 minutes or less on April 11, 2018 at the event. Giving Circle members are the voters who will determine winners. Absentee voters will be given the option to vote online.
Winners will be announced that night or the next day at the Symposium, to be determined.
To date, the pursuit of disease-modifying therapy development for Alzheimer's disease (AD) has been primarily informed by the study of diseased individuals, often by comparing genomic and other molecular, cellular and physiologic features in AD cases and controls. This has proven extremely challenging given the disease's heterogeneity and its multifactorial etiology. There is a growing appreciation that the development of effective treatment and prevention for complex diseases such as AD can benefit from gaining a much deeper understanding of what it means to be well and which genomic, epigenomic, environmental, social, and behavioral factors promote wellness and protection against disease.
This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research that results in a comprehensive view of the dynamic, multidimensional tumor ecosystem. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Generation of Human Tumor Atlases.
For the purposes of this FOA, a human pre-cancer atlas is defined as a multidimensional cellular, morphological and molecular mapping of human pre-malignant tumors, complemented with critical spatial information (at cellular and/or molecular level) that facilitate visualization of the structure, composition, and multiscale interactions within the tumor ecosystem over time resulting in progression or regression of the tumors.
This solicitation extends the Collaborative Research in Computational Neuroscience program for three years. Proposals for collaborations involving Japan are now supported through a new partnership with the National Institute of Information and Communications Technology. Please see the proposal preparation instructions and country-specific instructions and limitations in Sections V and VIII of this solicitation, and the companion documents published by CRCNS partner agencies referenced in Section VIII.
The description of scientific topics and approaches has been updated in Section II of this solicitation.
Agency contacts have been updated in Section VIII.
Results from prior NSF, NIH, and/or CRCNS support must be included in the Project Description if any PI or co-PI identified on the project has received NSF funding, NIH funding, or CRCNS funding from another participating agency, with a start date in the past five years.
The purpose of this FOA is to support investigator-initiated R21 applications that will inform our understanding of the typical and atypical patterns of language and literacy development of dual language learners (DLLs) in the United States. Applicants are encouraged to take advantage of advances in the language sciences and related fields to identify and clarify specific cognitive, linguistic, neurobiological, and sociocultural factors associated with normal and impaired language and literacy acquisition in young DLL populations.
Made possible through a 12-year, $50 million commitment from the Amgen Foundation, Amgen Scholars allows undergraduates from across the globe to participate in cutting-edge research opportunities at world-class institutions. 17 leading institutions across the U.S., Europe and Japan currently host the summer program.
Undergraduate participants benefit from undertaking a research project under top faculty, being part of a cohort-based experience of seminars and networking events, and taking part in a symposium in their respective region (U.S., Europe or Japan) where they meet their peers, learn about biotechnology, and hear from leading scientists.
-- No previous research experience is necessary and you do not need to be a biology major to apply.
-- You do not need to currently attend one of the 17 host institutions to participate in the program.
-- During the program, students work full-time on independent research projects under the guidance of a research scientist.
-- Amgen Scholars have opportunities to conduct research, analyze data, present research results, network with other undergraduates with similar research interests, and develop working relationships with faculty mentors and other research staff.
-- Financial support is a critical component of the Amgen Scholars Program. Please note that details vary by host institution. See each institution's Amgen Scholars Program website for more information.
National Science Foundation's Major Research Instrumentation Program (MRI) assists in the acquisition or development of major research instrumentation. This program seeks to improve the quality and expand the scope of research and research training in science and engineering, and to foster the integration of research and education by providing instrumentation for research-intensive learning environments. The MRI program also encourages the shared inter- and/or intra-organizational use of the acquired research instrumentation. For more information, please consult the program's guidelines.
Miami University may submit up to three MRI proposals (up to two that request between $100,000 and $1 million and no more than one that requests between $1 million and $4 million) on which Miami is either the lead or a partner institution. To facilitate the selection of our submissions to NSF, we have set a deadline of October 28, 2019 to receive preliminary MRI proposals for internal review. You are required to provide a preliminary proposal regardless of whether you were selected as an institutional submission in previous years.
The purpose of this funding opportunity announcement (FOA) is to stimulate research to understand the biological basis by which environmental exposures alter brain and behavioral functioning to increase risk for psychiatric disorders with onset in late-childhood, adolescence or early adulthood. A range of approaches are encouraged, from mechanistic experiments using whole organism models or in vitro and in vivo systems to human studies that add new data collection activities and/or make use of extant data or biospecimens. Investigations that further advance our understanding of the joint contribution of genes and environment in the risk for psychiatric disorders are welcomed. Applications should address either categorically defined psychiatric diagnoses and/or continuous traits expressed in the general population. Applicants are encouraged to propose studies that consider co-occurring psychiatric conditions and potential shared etiologies. It is anticipated that knowledge gained from the research supported by this FOA will inform the development of improved intervention, prevention and/or therapeutic strategies.
Also listed under R21.
This funding opportunity aims to stimulate multi-disciplinary collaboration and secondary analyses of existing clinical research datasets, from two or more multi-site clinical research studies, for addressing scientific and / or clinically relevant hypotheses that have the potential to address knowledge gaps to inform future clinical trials and/or improve clinical care in research areas within the NINDS mission. For purposes of this RFA, "existing clinical research datasets" refers to datasets from clinical trials, natural history studies, and / or comparative effectiveness research studies but excludes "mechanistic clinical studies" and "basic experimental studies of humans" (for definitions see https://grants.nih.gov/grants/guide/notice-files/NOT-NS-18-011.html and https://grants.nih.gov/grants/glossary.htm#BasicExperimentalStudieswithHumans, respectively). This RFA will support the curation and analyses of datasets from two or more multi-site clinical research studies to conduct additional secondary analyses; it will not support the collection of new data.
Despite established associations between white matter lesions and cognitive impairment including dementia, little prospective information is available to define the characteristics of white matter lesions and associated comorbid clinical factors that cause further cognitive impairment, ultimately resulting in dementia. This initiative will support one large prospective clinical research study in the U.S. of patients engaged with the health care system because of incidental white matter lesions found on neuroimaging, who present with cognitive complaints, and who thus are at risk for cognitive decline. The goal will be to determine the volume and anatomical features that are both necessary and sufficient to cause cognitive impairment or dementia.
The purpose of this Funding Opportunity Announcement (FOA) is to support investigators who have interest and capability to join efforts for the discovery of in vivo chemical probes for novel brain targets. It is expected that applicants will have, in hand, the starting compounds ("validated hits") for chemical optimization and bioassays for testing new analog compounds.
Through this FOA, NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in understanding biological processes relevant to the missions of NIMH, NIDA, NEI, and/or NIA and 2) discovery and/or validation of novel, biological targets that will inform studies of brain disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease-related biological targets and biological processes.
The main emphasis of projects submitted under this FOA should be the discovery of in vivo chemical probes. Applicants interested in developing cell-based chemical probes may wish to apply using the companion R21 mechanism, (PAR-21-028).
NIH's $40M fiscal year 2014 investment in the BRAIN Initiative will focus on nine areas of research. The vision for the initiative is to combine these areas of research into a coherent, integrated science of cells, circuits, brain and behavior.
Generate a census of brain cell types
Create structural maps of the brain
Develop new, large-scale neural network recording capabilities
Develop a suite of tools for neural circuit manipulation
Link neuronal activity to behavior
Integrate theory, modeling, statistics and computation with neuroscience experiments
Delineate mechanisms underlying human brain imaging technologies
Create mechanisms to enable collection of human data for scientific research
Disseminate knowledge and training
The purpose of this award is to provide salary and research support for up to three years for a new academic clinician-scientist at the Assistant Professor level, in order to facilitate his or her development into an independent otologic investigator.
